Login Register Cart 0
Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in Chinese
Review Article

Nano-biofilm Arrays as a Novel Universal Platform for Microscale Microbial Culture and High-Throughput Downstream Applications

Author(s): Anand Srinivasan, Anand K. Ramasubramanian and José L. Lopez-Ribot*

Volume 26, Issue 14, 2019

Page: [2529 - 2535] Pages: 7

DOI: 10.2174/0929867326666190107155953

Price: $65

Abstract

Biofilms are the predominant mode of microbial growth and it is now fully accepted that a majority of infections in humans are associated with a biofilm etiology. Biofilms are defined as attached and structured microbial communities surrounded by a protective exopolymeric matrix. Importantly, sessile microorganisms growing within a biofilm are highly resistant to antimicrobial agents. Thus, there is an urgent need to develop new and improved anti-biofilm therapies. Unfortunately, most of the current techniques for in-vitro biofilm formation are not compatible with high throughput screening techniques that can speed up discovery of new drugs with anti-biofilm activity. To try to overcome this major impediment, our group has developed a novel technique consisting of micro-scale culture of microbial biofilms on a microarray platform. Using this technique, hundreds to thousands of microbial biofilms, each with a volume of approximately 30-50 nanolitres, can be simultaneously formed on a standard microscope slide. Despite more than three orders of magnitude of miniaturization over conventional biofilms, these nanobiofilms display similar growth, structural and phenotypic properties, including antibiotic drug resistance. These nanobiofilm chips are amenable to automation, drastically reducing assay volume and costs. This technique platform allows for true high-throughput screening in search for new anti-biofilm drugs.

Keywords: Biofilms, microarray, biofilm chip, microscale culture, high throughput screening, drug development.

« Previous Next »
[1]
Costerton, J.W.; Cheng, K.J.; Geesey, G.G.; Ladd, T.I.; Nickel, J.C.; Dasgupta, M.; Marrie, T.J. Bacterial biofilms in nature and disease. Annu. Rev. Microbiol., 1987, 41, 435-464. [http://dx.doi.org/10.1146/annurev.mi.41.100187.002251]. [PMID: 3318676].
[2]
Donlan, R.M. Biofilms: Microbial life on surfaces. Emerg. Infect. Dis., 2002, 8(9), 881-890. [http://dx.doi.org/10.3201/eid0809.020063]. [PMID: 12194761].
[3]
Costerton, J.W.; Stewart, P.S.; Greenberg, E.P. Bacterial biofilms: a common cause of persistent infections. Science, 1999, 284(5418), 1318-1322. [http://dx.doi.org/10.1126/science.284.5418.1318]. [PMID: 10334980].
[4]
Donlan, R.M.; Costerton, J.W. Biofilms: Survival mechanisms of clinically relevant microorganisms. Clin. Microbiol. Rev., 2002, 15(2), 167-193. [http://dx.doi.org/10.1128/CMR.15.2.167-193.2002]. [PMID: 11932229].
[5]
Darouiche, R.O. Treatment of infections associated with surgical implants. N. Engl. J. Med., 2004, 350(14), 1422-1429. [http://dx.doi.org/10.1056/NEJMra035415]. [PMID: 15070792].
[6]
Raad, I. Intravascular-catheter-related infections. Lancet, 1998, 351(9106), 893-898. [http://dx.doi.org/10.1016/S0140-6736(97)10006-X]. [PMID: 9525387].
[7]
Fux, C.A.; Costerton, J.W.; Stewart, P.S.; Stoodley, P. Survival strategies of infectious biofilms. Trends Microbiol., 2005, 13(1), 34-40. [http://dx.doi.org/10.1016/j.tim.2004.11.010]. [PMID: 15639630].
[8]
Talsma, S.S. Biofilms on medical devices. Home Healthc. Nurse, 2007, 25(9), 589-594. [http://dx.doi.org/10.1097/01.NHH.0000296117.87061.14]. [PMID: 18049256].
[9]
de la Fuente-Núñez, C.; Reffuveille, F.; Fernández, L.; Hancock, R.E. Bacterial biofilm development as a multicellular adaptation: Antibiotic resistance and new therapeutic strategies. Curr. Opin. Microbiol., 2013, 16(5), 580-589. [http://dx.doi.org/10.1016/j.mib.2013.06.013]. [PMID: 23880136].
[10]
Lara, H.H.; Romero-Urbina, D.G.; Pierce, C.; Lopez-Ribot, J.L.; Arellano-Jiménez, M.J.; Jose-Yacaman, M. Effect of silver nanoparticles on Candida albicans biofilms: An ultrastructural study. J. Nanobiotechnology, 2015, 13, 91. [http://dx.doi.org/10.1186/s12951-015-0147-8]. [PMID: 26666378].
[11]
Pierce, C.G.; Srinivasan, A.; Ramasubramanian, A.K.; López-Ribot, J.L. From biology to drug development: New approaches to combat the threat of fungal biofilms. Microbiol. Spectr., 2015, 3(3) [http://dx.doi.org/10.1128/microbiolspec.MB-0007-2014]. [PMID: 26185082].
[12]
Gefen, O.; Balaban, N.Q. The Moore’s Law of microbiology - towards bacterial culture miniaturization with the micro-Petri chip. Trends Biotechnol., 2008, 26(7), 345-347. [http://dx.doi.org/10.1016/j.tibtech.2008.03.007]. [PMID: 18453020].
[13]
Srinivasan, A.; Lopez-Ribot, J.L.; Ramasubramanian, A.K. Microscale microbial culture. Future Microbiol., 2015, 10(2), 143-146. [http://dx.doi.org/10.2217/fmb.14.129]. [PMID: 25689525].
[14]
Weibull, E.; Antypas, H.; Kjäll, P.; Brauner, A.; Andersson-Svahn, H.; Richter-Dahlfors, A. Bacterial nanoscale cultures for phenotypic multiplexed antibiotic susceptibility testing. J. Clin. Microbiol., 2014, 52(9), 3310-3317. [http://dx.doi.org/10.1128/JCM.01161-14]. [PMID: 24989602].
[15]
Banerjee, S.N.; Emori, T.G.; Culver, D.H.; Gaynes, R.P.; Jarvis, W.R.; Horan, T.; Edwards, J.R.; Tolson, J.; Henderson, T.; Martone, W.J. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. Am. J. Med., 1991, 91(3B), 86S-89S. [http://dx.doi.org/10.1016/0002-9343(91)90349-3]. [PMID: 1928197].
[16]
Gudlaugsson, O.; Gillespie, S.; Lee, K.; Vande Berg, J.; Hu, J.; Messer, S.; Herwaldt, L.; Pfaller, M.; Diekema, D. Attributable mortality of nosocomial candidemia, revisited. Clin. Infect. Dis., 2003, 37(9), 1172-1177. [http://dx.doi.org/10.1086/378745]. [PMID: 14557960].
[17]
Hajjeh, R.A.; Sofair, A.N.; Harrison, L.H.; Lyon, G.M.; Arthington-Skaggs, B.A.; Mirza, S.A.; Phelan, M.; Morgan, J.; Lee-Yang, W.; Ciblak, M.A.; Benjamin, L.E.; Sanza, L.T.; Huie, S.; Yeo, S.F.; Brandt, M.E.; Warnock, D.W. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J. Clin. Microbiol., 2004, 42(4), 1519-1527. [http://dx.doi.org/10.1128/JCM.42.4.1519-1527.2004]. [PMID: 15070998].
[18]
Ramage, G.; Martínez, J.P.; López-Ribot, J.L. Candida biofilms on implanted biomaterials: a clinically significant problem. FEMS Yeast Res., 2006, 6(7), 979-986. [http://dx.doi.org/10.1111/j.1567-1364.2006.00117.x]. [PMID: 17042747].
[19]
Ramage, G.; Mowat, E.; Jones, B.; Williams, C.; Lopez-Ribot, J. Our current understanding of fungal biofilms. Crit. Rev. Microbiol., 2009, 35(4), 340-355. [http://dx.doi.org/10.3109/10408410903241436]. [PMID: 19863383].
[20]
Ostrosky-Zeichner, L.; Casadevall, A.; Galgiani, J.N.; Odds, F.C.; Rex, J.H. An insight into the antifungal pipeline: selected new molecules and beyond. Nat. Rev. Drug Discov., 2010, 9(9), 719-727. [http://dx.doi.org/10.1038/nrd3074]. [PMID: 20725094].
[21]
Pierce, C.G.; Srinivasan, A.; Uppuluri, P.; Ramasubramanian, A.K.; López-Ribot, J.L. Antifungal therapy with an emphasis on biofilms. Curr. Opin. Pharmacol., 2013, 13(5), 726-730. [http://dx.doi.org/10.1016/j.coph.2013.08.008]. [PMID: 24011516].
[22]
Srinivasan, A.; Uppuluri, P.; Lopez-Ribot, J.; Ramasubramanian, A.K. Development of a high-throughput Candida albicans biofilm chip. PLoS One, 2011, 6(4)e19036 [http://dx.doi.org/10.1371/journal.pone.0019036]. [PMID: 21544190].
[23]
Srinivasan, A.; Leung, K.P.; Lopez-Ribot, J.L.; Ramasubramanian, A.K. High-throughput nano-biofilm microarray for antifungal drug discovery. MBio, 2013, 4(4), e00331-e13. [http://dx.doi.org/10.1128/mBio.00331-13]. [PMID: 23800397].
[24]
Tibbitt, M.W.; Anseth, K.S. Hydrogels as extracellular matrix mimics for 3D cell culture. Biotechnol. Bioeng., 2009, 103(4), 655-663. [http://dx.doi.org/10.1002/bit.22361]. [PMID: 19472329].
[25]
Chandra, J.; Kuhn, D.M.; Mukherjee, P.K.; Hoyer, L.L.; McCormick, T.; Ghannoum, M.A. Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J. Bacteriol., 2001, 183(18), 5385-5394. [http://dx.doi.org/10.1128/JB.183.18.5385-5394.2001]. [PMID: 11514524].
[26]
Ramage, G.; Vandewalle, K.; Wickes, B.L.; López-Ribot, J.L. Characteristics of biofilm formation by Candida albicans. Rev. Iberoam. Micol., 2001, 18(4), 163-170. [PMID: 15496122].
[27]
Ramage, G.; Vande Walle, K.; Wickes, B.L.; López-Ribot, J.L. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob. Agents Chemother., 2001, 45(9), 2475-2479. [http://dx.doi.org/10.1128/AAC.45.9.2475-2479.2001]. [PMID: 11502517].
[28]
Uppuluri, P.; Srinivasan, A.; Ramasubramanian, A.; Lopez-Ribot, J.L. Effects of fluconazole, amphotericin B, and caspofungin on Candida albicans biofilms under conditions of flow and on biofilm dispersion. Antimicrob. Agents Chemother., 2011, 55(7), 3591-3593. [http://dx.doi.org/10.1128/AAC.01701-10]. [PMID: 21518839].
[29]
Srinivasan, A.; Gupta, C.M.; Agrawal, C.M.; Leung, K.P.; Lopez-Ribot, J.L.; Ramasubramanian, A.K. Drug susceptibility of matrix-encapsulated Candida albicans nano-biofilms. Biotechnol. Bioeng., 2014, 111(2), 418-424. [http://dx.doi.org/10.1002/bit.25120]. [PMID: 24114441].
[30]
Srinivasan, A.; Torres, N.S.; Leung, K.P.; Lopez-Ribot, J.L.; Ramasubramanian, A.K. nBioChip, a lab-on-a-chip platform of mono- and polymicrobial biofilms for high-throughput downstream applications. MSphere, 2017, 2(3), e00247-e17. [http://dx.doi.org/10.1128/mSphere.00247-17]. [PMID: 28680970].
[31]
Srinivasan, A.; Lee, G.C.; Torres, N.S.; Hernandez, K.; Dallas, S.D.; Lopez-Ribot, J.; Frei, C.R.; Ramasubramanian, A.K. High-throughput microarray for antimicrobial susceptibility testing. Biotechnol. Rep. (Amst.), 2017, 16, 44-47. [http://dx.doi.org/10.1016/j.btre.2017.10.004]. [PMID: 29167758].
[32]
Wisplinghoff, H.; Bischoff, T.; Tallent, S.M.; Seifert, H.; Wenzel, R.P.; Edmond, M.B. Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis., 2004, 39(3), 309-317. [http://dx.doi.org/10.1086/421946]. [PMID: 15306996].
[33]
Wolcott, R.; Costerton, J.W.; Raoult, D.; Cutler, S.J. The polymicrobial nature of biofilm infection. Clin. Microbiol. Infect., 2013, 19(2), 107-112. [http://dx.doi.org/10.1111/j.1469-0691.2012.04001.x]. [PMID: 22925473].

Rights & Permissions Print Cite
Article Metrics
38
2
World Chagas Disease
© 2024 Bentham Science Publishers | Privacy Policy